Clinical Trial

RGL-270 + ICI in Advanced NSCLC

Recruiting
View on ClinicalTrials.gov →
Summary
This is a single-center, open-label, investigator-initiated clinical trial. It aims to evaluate the safety and tolerability of RGL-270 in combination with a PD-1/PD-L1 inhibitor, to assess immunogenicity, preliminary efficacy, and exploratory biomarkers and to observe the safety and effectiveness of PD-1/PD-L1 inhibitor monotherapy in advanced NSCLC subjects through a real-world observational cohort.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-01
notable Primary completion pushed: 2027-06 -> 2027-12-31 2026-07-01
minor Completion moved earlier: 2028-06 -> 2027-12-31 2026-07-01
Trial Details
NCT Number NCT07652125
Lead Sponsor Guangdong Association of Clinical Trials
Collaborators: Shanghai Regenelead Theraples,Co,Ltd.
Conditions NSCLC
Enrollment 40 participants
Start Date 2025-10-25
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-30